Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: A targeted metabolomics study

Liu, Yi-yun; Song, Xuemian; Liu, Xinyu; Pu, Juncai; Gui, Siwen; Xu, Shaohua; Tian, Lu; Zhong, Xiaogang; Zhao, Libo; Wang, Haiyang; Liu, Lanxiang; Xu, Guowang; Xie, Peng

doi:10.1111/pcn.13194

Cited by 26 publications

(23 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast, targeted metabolomics provides a robust, highthroughput identification of preselected, defined groups of annotated metabolites with internal standards (32). Compared with the untargeted, targeted metabolomics has superior selective and sensitive performance while providing reproducible data (33).…”

Section: Metabolic Alterations In Schizophreniamentioning

confidence: 99%

Metabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players

Molina

Avila

Rubio

et al. 2021

CPD

View full text Add to dashboard Cite

Background: Diagnosis of schizophrenia lacks of reliable medical diagnostic tests and robust biomarkers applied to clinical practice. Schizophrenic patients undergoing treatment with antipsychotics suffer a reduced life expectancy due to metabolic disarrangements that co-exist with their mental illness and predispose them to develop metabolic syndrome, also exacerbated by medication. Metabolomics is an emerging and potent technology able to accelerate this biomedical research. Aim: This review focus on a detailed vision of the molecular mechanisms involved both in schizophrenia and antipsychotic-induced metabolic syndrome, based on innovative metabolites that consistently change in nascent metabolic syndrome, drug-naïve, first episode psychosis and/or schizophrenic patients compared to healthy subjects. Main lines: Supported by metabolomic approaches, although not exclusively, noteworthy variations are reported mainly through serum samples of patients and controls in several scenes: 1) alterations in fatty acids, inflammatory response indicators, amino acids and biogenic amines, biometals and gut microbiota metabolites (schizophrenia); 2) alterations in metabolites involved in carbohydrate and gut microbiota metabolism, inflammation and oxidative stress (metabolic syndrome), some of them shared with the schizophrenia scene; 3) alterations of cytokines secreted by adipose tissue, phosphatidylcholines, acylcarnitines, Sirtuin 1, orexin-A and changes in microbiota composition (antipsychotic-induced metabolic syndrome). Conclusion: Novel insights into the pathogenesis of schizophrenia and metabolic side-effects associated to its antipsychotic treatment, represent an urgent request for scientifics and clinicians. Leptin, carnitines, adiponectin, insulin or interleukin-6 represent some examples of candidate biomarkers. Cutting-edge technologies like metabolomics have the power of strengthen research for achieving preventive, diagnostic and therapeutical solutions for schizophrenia.

show abstract

Section: Metabolic Alterations In Schizophreniamentioning

confidence: 99%

Metabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players

Molina

Avila

Rubio

et al. 2021

CPD

View full text Add to dashboard Cite

show abstract

“…The biological functions of lipids are associated with multiple processes, including inflammation, apoptosis, proliferation, and differentiation ( 36 , 37 ), and disturbances in lipid metabolism have been demonstrated in various neuropsychiatric diseases ( 38 , 39 ). Although changes in plasma lipids have also been observed in mental disorders, including schizophrenia, depression, and BD ( 40 , 41 ), we believe that the current study is the first study to quantitatively compare plasma lipid composition in adult women with BD vs. HCs. Herein we found that the levels of SM, AcCa, PE, PS, and Co decreased in BD and were negatively correlated with the severity of psychotic, affective, or mania symptoms.…”

Section: Discussionmentioning

confidence: 89%

Alterations in the Plasma Lipidome of Adult Women With Bipolar Disorder: A Mass Spectrometry-Based Lipidomics Research

Guo¹,

Zhang²,

Li³

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

Lipidomics has become a pivotal tool in biomarker discovery for the diagnosis of psychiatric illnesses. However, the composition and quantitative analysis of peripheral lipids in female patients with bipolar disorder (BD) have been poorly addressed. In this study, plasma samples from 24 female patients with BD and 30 healthy controls (HCs) were analyzed by comprehensive lipid profiling and quantitative validation based on liquid chromatography–mass spectrometry. Clinical characteristics and a correlation between the level of lipid molecules and clinical symptoms were also observed. We found that the quantitative alterations in several lipid classes, including acylcarnitine, lysophosphatidylethanolamine, GM2, sphingomyelin, GD2, triglyceride, monogalactosyldiacylglycerol, phosphatidylinositol phosphate, phosphatidylinositol 4,5-bisphosphate, phosphatidylethanolamine, phosphatidylserine, and lysophosphatidylinositol, were remarkably upregulated or downregulated in patients with BD and were positively or negatively correlated with the severity of psychotic, affective, or mania symptoms. Meanwhile, the composition of different carbon chain lengths and degrees of fatty acid saturation for these lipid classes in BD were also different from those of HCs. Moreover, 55 lipid molecules with significant differences and correlations with the clinical parameters were observed. Finally, a plasma biomarker set comprising nine lipids was identified, and an area under the curve of 0.994 was obtained between patients with BD and the HCs. In conclusion, this study provides a further understanding of abnormal lipid metabolism in the plasma and suggests that specific lipid species can be used as complementary biomarkers for the diagnosis of BD in women.

show abstract

“…MRM analysis by Liu et al . ( 68 ) partly validated these dysregulated phospholipid homeostasis findings, identifying several FFA, AC intermediates, along with phosphatidylcholine (PC) and LPC in plasma of individuals with SCZ compared to matched controls, adding to their biomarker candidacy.…”

Section: Lipidomics Investigations Into Ssd and Psychosis Fluid Bioma...mentioning

confidence: 90%

Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review

et al. 2022

View full text Add to dashboard Cite

Schizophrenia spectrum disorders (SSD) are traditionally diagnosed and categorized through clinical assessment, owing to their complex heterogeneity and an insufficient understanding of their underlying pathology. However, disease progression and accurate clinical diagnosis become problematic when differentiating shared aspects amongst mental health conditions. Hence, there is a need for widely accessible biomarkers to identify and track the neurobiological and pathophysiological development of mental health conditions, including SSD. High-throughput omics applications involving the use of liquid chromatography-mass spectrometry (LC-MS) are driving a surge in biological data generation, providing systems-level insight into physiological and pathogenic conditions. Lipidomics is an emerging subset of metabolomics, largely underexplored amongst the omics systems. Lipid profiles in the brain are highly enriched with well-established functions, including maintenance, support, and signal transduction of neuronal signaling pathways, making them a prospective and exciting source of biological material for neuropsychiatric research. Importantly, changes in the lipid composition of the brain appear to extend into the periphery, as there is evidence that circulating lipid alterations correlate with alterations of psychiatric condition(s). The relative accessibility of fluid lipids offers a unique source to acquire a lipidomic “footprint” of molecular changes, which may support reliable diagnostics even at early disease stages, prediction of treatment response and monitoring of treatment success (theranostics). Here, we summarize the latest fluid lipidomics discoveries in SSD-related research, examining the latest strategies to integrate information into multi-systems overviews that generate new perspectives of SSD-related psychosis identification, development, and treatment.

show abstract

Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: A targeted metabolomics study

Cited by 26 publications

References 47 publications

Metabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players

Metabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players

Alterations in the Plasma Lipidome of Adult Women With Bipolar Disorder: A Mass Spectrometry-Based Lipidomics Research

Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review

Contact Info

Product

Resources

About